
VASP LineA solution for your every need



A tailored clopidogrel loading dose according to platelet reactivity monitoring decreases the rate of early stent thrombosis after PCI without increasing bleeding "

BONELLO L. et al.: Am J Cardiol. 2009; 103:5-10

This assay has demonstrated its high sensitivity and specificity for clopidogrel treatment [...] one advantage of this test is the stability of the blood samples "

ALEIL B. et al; Thromb Haemost. 2005; 94:886-7

Our data provide evidence that the PLT VASP/P2Y12 assay [...] appeared to be specific most towards the effects of clopidogrel and, thus, might be the most useful test for the assessment of clopidogrel action among the evaluated methods "

MUELLER T. et al.: Thromb Research. 2007; 121:249-258

BIBLIOGRAPHY

- 1. BARRAGAN P. et al.; CCI 2003; 59:295-302
- 2. ALEIL B. et al; J Thromb Haemost. 2005; 3:85-92
- 3. ALEIL B. et al; Thromb Haemost. 2005; 94:886-7 4. PAMPUCH A. et al.: Thromb Haemost. 2006; 96:767-73
- FAMIFOCH A. et al.: Thromb Research. 2000; 90.767-73
 GURBEL PA. et al.:Thromb Research. 2007; 120:311–321
- 6. BONELLO L. et al.; J Thromb Haemost. 2007; 8:1630-6
- 7. JAKUBOWSKI J. et al.: Thromb Haemost. 2007; 99:215-222
- 8. MUELLER T. et al.: Thromb Research. 2007; 121:249-258
- 9. WIVIOTT SD, et al.: Circulation. 2007; 116:2923-2932 10. BLINDT R. et al.: Thromb Haemost. 2007; 98:1329-1334
- 11. BONELLO L. et al.: Am J Cardiol. 2009; 103:5-10
- 12. GURBEL PA, et al.: Circulation. 2009; 120:2577-85
- 13. BARRAGAN P. et al.: Thromb Haemost. 2010; 104:410-411 14. BONELLO L. et al.: JACC. 2010; Vol. 56, No. 12; 919–33
- 15. JAKUBOWSKI J. et al.: Thromb Haemost. 2012; 107:388-395




A Stago Group Company

For further information, please contact:



Diagnostica Stago S.A.S RCS Nanterre B305 151 409 9, rue des Frères Chausson 92600 Asnières sur Seine (France) Ph. +33 (0)1 46 88 20 20 Fax +33 (0)1 47 91 08 91 webmaster@stago.com www.stago.com




Discover our complete solution for anti-P2Y12 drugs monitoring



Why choose **VASP** for anti-P2Y12 drugs monitoring?

Benefits of VASP as a biomarker



ADP: Adenosine Diphosphate
P2Y12: ADP receptor
AC: Adenylate Cyclase
PGE1: Prostaglandin E1
cAMP: cyclic Adenosine MonoPhosphate
PKA: Phosphokinase A
VASP: Vasodilator Stimulated Phosphoproteir
VASP-P: Phosphorylated VASP

A specific biomarker

- P2Y12 is an ADP receptor selectively inhibited by different antiplatelet drugs
- VASP (VAsodilator Stimulated Phosphoprotein) is an intracellular platelet protein that at basal state is unphosphorylated
- VASP phosphorylation correlates with the P2Y12 receptor inhibition, whereas its non-phosphorylation state correlates with the active form of P2Y12 receptor
- VASP is the **most specific biomarker** of P2Y12 inhibition:
- With no interference from other ADP receptors such as P2Y1, as compared to aggregation based assays^{7,8}
- Insensitive to Aspirin and anti-aggregant drugs (Reopro® and Integrelin®)
- Insensitive to WWF level and Platelet count, as compared to shear force assays
- Results in PRI (%): Platelet Reactivity Index, calculated in the presence of PGE1 alone or PGE1+ADP simultaneously.
- The lower PRI is, the higher P2Y12 inhibition is.


Easy to collect...

- Can be used with all standard coagulation tubes
- No need for expensive and uncommon anticoagulant
- Only small volumes for fresh citrated whole blood are needed (< 80 µL)

...Easy to process

- Easy sample handling: **stability up to 48h** at room temperature after blood collection (compared to < 4h for aggregation based assays)³
- Allows **sample transportation** and batch testing by reference laboratory³





Kaplan-Meier curve of freedom of definite stent thrombosis survival according to groups BONELLO L. et al. Am J. Cardiol. 2009

Applications

- Why monitor P2Y12 antagonists?
 - Up to 44% of treated patients are considered "resistant" to Clopidogrel⁵
 - Insufficient platelet inhibition leads to risks of adverse cardiovascular events after percutaneous interventions (PCI)¹⁴
- VASP is widely published as a clinical tool for anti-P2Y12 monitoring 1,2,6,10
- In a 2009 study from Bonello et al., the rate of early stent thrombosis was 4.7% in the control group vs 0.5% in the VASP guided group (p<0.01)¹¹
- PubMed citations: >1000 publications
- Largely used for drug discovery and validation of new P2Y12 antagonists as well

Assayed Drugs

Commercial Drugs

- Ticlid® (Ticlopidine)1
- Ticila (Ticiopianie)
- Plavix® (Clopidogrel)¹
 Efient®/Effient® (Prasugrel)³
- Brilique® (Ticagrelor)12

Under Development Drugs

Cangrelor⁴

Ticlid® and Plavix® are registered trademarks of Sanofi-Aventis Efient®/Effient® is a registered trademark of Eli Lilly-Daiichi Sankyo Brilique® is a registered trademark of AstraZeneca


Take advantage of your **VASP** based-assays

The reference assays for specific platelet ADP receptor (P2Y12) antagonists

The "Gold Standard" on Flow Cytometer: PLT VASP/P2Y12

Cat. Nr. 00449 - CE Marked

- Specifically designed for P2Y12 antagonist monitoring
- Unique patented antibody against phosphorylated VASP (clone 16C2) 10¹
- Only 30 μL citrated whole blood needed
- Sample stability up to 48h at room temperature
- Kit size suitable for low to medium activity (from 1 to 10 tests per run)
- Quick result: protocol < 30 minutes</p>
- Standardised & reproducible Flow Cytometer protocol
- Compatible with all types of Flow Cytometer






An innovative whole-blood ELISA: CY-QUANT VASP/P2Y12*

Cat. Nr. 01076 - CE Marked

- A 96-well microplate based adaptation of PLT VASP/P2Y12 gold standard assay^{13,15}
- Highly significant correlation with the PLT VASP/P2Y12 assay (n=80; r=0.95; p<0.001)¹⁵
- Only 80 μL citrated whole blood needed
- Sample stability up to 24h at room temperature
- Kit size suitable for **low to high activity** (from 1 to 47 tests per run)
- Easy to use & compatible with all types of microplate reader (450 nm)





* Available depending upon the country